Cymbalta Withdrawal Solution, Duloxetine Side Effects, Treatment Options
Cymbalta Withdrawal Symptoms
The majority of people attempting Cymbalta withdrawal experience an
antidepressant withdrawal syndrome. This is also known as Cymbalta
discontinuation syndrome in the United States. In Europe it is call Cymbalta
withdrawal side effects. The F.D.A. estimates 10% of those experiencing Cymbalta
withdrawal will go back up on the Cymbalta because the withdrawal symptoms are
too severe.
If you want to read the short version of how to handle Cymbalta withdrawal side effects
Click here. Page opens new browser window.
The most common and debilitating Cymbalta withdrawal side effect is called
"brain zaps." Brain zaps are described by people experiencing it as a; electrical jolt
that tends to run from base of the neck up into their head. Another side effect that
tends to run with brain zaps is a shiver, a feeling as your head is floating, dizziness,
and/or a whirling sensation in the head.
These symptoms can come in waves or even be persistent.
The good news; in 2002, our founder, Jim Harper, discovered the correct type of
Omega 3 taken in the right quantity will eliminate these devastating head
symptoms quickly. Usually within a couple of hours.
The body in a normal state uses the oil from our diet, specifically from omega 3
found in fish, to build and replenish the end point of areas in the brain that sends
and receives electrical signals. We are using easy to understand terminology here
so it is easy to understand. Let's leave the technical jargon to physicians.
These brain zaps have nothing to do with serotonin levels or other made up
reasons. It is simple really; our body works in a very natural way with how it uses
amino acids, proteins, fats in food and all other diet items to maintain a balance.
When you introduce any toxin that disrupts these processes the body reacts.
The most common Cymbalta Duloxetine withdrawal symptoms reported include:
Flu like symptoms
Insomnia
Anxiety
Brain zaps
Tremors
Diarrhea
Vomiting
Increased suicidal ideation
Nausea
Headache
Mania
Hypomania
Ringing in the ears
Aggression
Confusion
Imbalance
Mood swings
Please note: These are the most common Cymbalta withdrawal side effects but far
from all potential Cymbalta withdrawal side effects.
There is a warning the FDA has put a black box warning on Cymbalta.
WARNING: SUICIDAL THOUGHTS AND BEHAVIORSSee full
prescribing information for complete boxed warning. Antidepressants
increased the risk of suicidal thoughts and behaviorsin pediatric and young
adult patients (5.1) Closely monitor for clinical worsening and emergence of
suicidalthoughts and behaviors
You may have been prescribed Cymbalta within a very short doctor visit. There
was no investigation into other life factors, lab testing, or any conversation about
what side effects might present. The failings of this approach may cause quite a
burden on the patient.
Depression, insomnia, anxiety, fibromyalgia, and other symptoms that Cymbalta is
often prescribed for might stem from; diminished vitamin D levels, over active
JNK gene, specific proteins that need to be silenced, dietary concerns and food
allergies, mitochondrial dysfunction, neurotoxic accumulation, and many other
reasons. A full physical from an understanding physician is ideal, before
prescribing Cymbalta.
Do Your Symptoms Require Cymbalta?
The Road Back Program uses nutritional supplements to help with the Cymbalta
withdrawal. Most people feel a very fast relief from the Cymbalta withdrawal once
they begin taking the supplements and we feel the odds are high; if would have
taken nutritional supplements like these before starting the Cymbalta you would
have been prescribed the Cymbalta in the first place.
In 2007, Jim Harper was giving a speech to a group of psychiatrists in Ireland and
during his talk he mentioned his mother just passed away 30 days ago. He went on
to describe how he made sure to take his JNK Formula each day to help the body
cope with the stress being put on it do to his loss. He went on to say, "The JNK
Formula will not remove the emotional loss and how I feel but it will keep the
body strong during my time to grieve."
How Do You Survive Cymbalta Withdrawal?
Surviving Cymbalta withdrawal depends on what you do at this very moment. If
you keep doing the same thing you have been doing and you are in a heavy
Cymbalta withdrawal, nothing will change for the positive, That is a given.
If you decide to do the Cymbalta withdrawal as an inpatient in a drug rehab center
DO NOT DO THE 9 DAY PLAN BECAUSE THAT WHAT INSURANCE
ALLOWS. Over the past 22 years I have worked with far to many people who
were sold on a rehab facility, stayed the 9 days because insurance would only pay
for that amount of time. The unscrupulous facility took them off the Cymbalta in 9
days as they promised and by the time the person got off the airplane after their
return home they were in full withdrawal. You can't do a Cymbalta withdrawal in 9
days.
The Road Back Program can normally help you get back on your feet again
but the rehab facility approach of this type is not worth the price you will pay
mentally and physically.
You will find a few other outpatient Cymbalta withdrawal programs on the internet
now and Jim Harper is not aware of one that will cause you harm like the rehab
facility's mentioned. However, every other program on the internet was trained by
Jim Harper years ago and they are doing what Jim Harper and The Road Back did
during that time frame. Almost 2 decades ago Jim Harper trained several
physicians and good intentioned people how to get a patient off Cymbalta. Jim
went in to detail of the process and what nutritional supplements were used and
why they were used. At that time of The Road Back the success rate was not as
high as desired and over the following years Jim changed the formulas used with
the supplements several times to use new information with DNA testing. Long
story short; you will likely wind up using a Cymbalta withdrawal approach The
Road Back used in 2003, that was scrapped for something more successful.
If you are currently in Cymbalta withdrawal, send Jim Harper an email and he will
personally guide you through the process so you can get back on your feet quickly
and have a very successful Cymbalta withdrawal.
It does not matter if you have been on Cymbalta for 1 month or 20 years. Recovery
can happen and the good part is; it does not take more time because you have been
taking Cymbalta for years.
When Do Cymbalta Withdrawal Symptoms Start When Discontinuing /
Quitting Cymbalta?
Cymbalta withdrawal usually begins between day 1 and day 3 of adjusting the
Cymbalta. For some people this is not the case but eventually most everyone hits
some dosage of the Cymbalta when reducing that jars them. Cymbalta withdrawal
begins and they have no idea what they should do. Their physician does not know
what to do. They wind up in a spiral downward and wind up on a new medication
to try and stop the Cymbalta withdrawal. The best case is the additional drug does
that but you are now on 2 drugs instead of only Cymbalta.
What is Cymbalta?
Cymbalta (sertraline) is an antidepressant medication developed in the 1970s
with
FDA approval granted in 1991. This SSRI drug is prescribed in treating adult
depressive disorders (MDD), panic disorder, obsessive compulsory disorders
(OCD), social anxiety (SAD), post-traumatic stress disorders (PTSD), and
premenstrual dysphoric disorder (PMDD).
If you have anxiety before taking Cymbalta, or anxiety begins while taking
Cymbalta, odds are the anxiety will continue to get worse. Cymbalta alters
dopamine much like the antidepressant Effexor and anxiety is a byproduct of these
two drugs.
What Is Cymbalta Used For?
Cymbalta (sertraline) is an antidepressant medication approved to treat adult MDD
(major depressive disorder). The Black Box warning on the drug’s packaging
mentions that the drug should not be prescribed to anyone under the age of 25, due
to heightened risk of suicide. There is an exception to this for patients under the
age of 25 who have been diagnosed with OCD (obsessive-compulsive disorder).
Potential suicidality is associated with all Cymbalta and may be a concern leading
to consider Cymbalta withdrawal, which is recommended to be done always under
medical or caregiver monitoring.
Adult-only approved uses for the drug provided in a clinical or treatment
setting include:
MDD: Major Depressive Disorder<
PTSD: Post-traumatic stress disorder
PD: Panic disorder
SAD: Social anxiety disorder
OCD: Obsessive-compulsive disorder
PMDD: Premenstrual dysphoric disorder
Cymbalta Side Effects
The full list of Cymbalta side effects is quite staggering. In 2004, Jim Harper used
the Freedom of Information Act to get the full list of Cymbalta side effects. Jim
received the information and it is 500 sheets of letter size paper, single space, a
number 10 font size, 3 columns per page. In other words, thousands of known
potential Cymbalta side effects were disclosed.
Some of the other Cymbalta and Cymbalta withdrawal side effects:
Serotonin syndrome: A life-threatening condition requiring immediate
medical care in a hospital emergency clinic or ICU. Symptoms to watch
for include sudden fever, losing consciousness, inability to move or
speak, copious sweating, dilated pupils, chills, tremors, convulsions,
diarrhea, agitation, restlessness, racing heart, etc.
Suicidal thoughts (common)
Suicide attempt (common)
Hyperkinesis (muscle spasms, movement disorder)
Worsened depression
Aggression
Paranoia (rare)
Anxiety
Mania (common)
Convulsions
Unconsciousness
Coma
Teeth grinding
Akathisia (relentless internal restlessness and discomfort marked by
repeated motions, pacing, rocking, etc., that can lead to suicidal
thoughts as a means of relief)
Tachycardia (racing heart, even when the body is at rest)
Rash
Itching
Burning, crawling feeling in the skin
Fever
Tics, sudden jerky movements, myoclonus
Emotional blunting
Behavioral apathy, SSRI-induced-indifference
Pain on urination or difficulty urinating
Cloudy urine
Headache
Sexual impairments, i.e., anorgasmia, inability to ejaculate, lowered
libido
Mood swings
Pain around the eyes or eye sockets
Sleepiness
Bladder pain
Prickling skin sensation
Numbness
Sensory disturbances
Insomnia
Depersonalization (common)
Nervousness
Nightmares (paroniria)
Hostility
Nausea
Diarrhea
Weight gain
Some documented Cymbalta birth defects and injuries include:
PPHN or persistent pulmonary hypertension of the newborn, a heart and
lung condition which can result in respiratory failure, decreased oxygen to
the brain, and multiple organ injuries.
Congenital Heart Defects connected to Cymbalta and other SSRIs include
ventricular septal defects and atrial septal defects, also referred to as “holes
in the heart”, related to heart murmurs, suppressed appetite, breathing
difficulties, tiredness, inadequate growth, etc.
Increased Risk of Autism has been extensively reported but evidence has
not yet been considered conclusive enough for regulatory bodies to ban
prescribing to pregnant women.
Increased Risk of Clubfoot connected to SSRIs during pregnancy as
reported by NIMH, where sertraline exposure had the highest increase in
clubfoot of all SSRIs.
Increased risk of atrial/ventricular defects and craniosynostosis was
reported in a Canadian study from 1998 to 2010 and published in the June
2015 issue of the American Journal of Gynecology & Obstetrics.
Cymbalta Withdrawal, What to Expect
If using The Road Back Program you should expect to feel a lot better within the
first couple days of the program. If you do nothing, expect to continue to feel as
you do now. Possibly worse as time goes on. The chance of feeling better if you do
nothing is nil.
In 1999, The Road Back only had people taper the Cymbalta gradually and slowly.
They still suffered. Around 50% could get off the Cymbalta but most went back on
the Cymbalta because they continual Cymbalta withdrawal side effects would not
diminish or go away.
We wish there was a better answer for you than the above but with working with
over 19 million people over the last 22 years, the truth is the truth. No way to water
it down to make it sound better.
Some may think it is just their depression returning but who would not feel
depressed if they were still going through Cymbalta withdrawal months after
stopping the Cymbalta.
We can't stress enough; what you do or do not do at this moment in time is critical
for your future. Take your time if at all possible. If you have brain zaps go buy any
omega 3 fish oil, even the wrong omega 3 fish oil will help somewhat.
While you read this you may want to pause and go take a walk. Look at the trees,
the sky or anything off in the distance. Getting your attention off your mind and
body may do wonders.
Keep this close to your heart; There is Hope and There is a Solution. We are
speaking directly to YOU.
A 30 day supply of the nutritional supplements will cost you around $80. If you
feel it is worth $80 to take a chance that all of this can go away in a couple of days,
then take that chance. Over the past 22 years many have sent an email to Jim
Harper and said they were not sure what to do about the Cymbalta withdrawal.
Even after reading this information. The people that tried something else generally
came back within a few months and were in worse shape than before. We do not
want this to happen to you. But if is; Jim will still be here to assist.
Can Cymbalta Make Depression Worse?
Common sense answers this question. If depression is one side effect of taking
Cymbalta then Cymbalta can cause depression. You do stand a greater chance of
Cymbalta causing depression during withdrawal than while simply taking the
Cymbalta as prescribed. The depression during Cymbalta withdrawal can be due to
the other Cymbalta withdrawal side effects you are experiencing. Who would not
start to get depressed if you have anxiety from morning to night, can't sleep and
your head feels like it is on fire.
Cymbalta Aggression in Children
Children are more prone to aggression when taking Cymbalta than adults. It
occurs in 10-20% of children taking any SSRI antidepressant. Two clinical trials
performed by Pfizer, aggression was the most common reason noted for Cymbalta
discontinuation.
Can You Get Addicted to Cymbalta?
Yes and no. This is where Cymbalta dependence is a matter of wording. Medically
speaking in the United States Cymbalta is not addicting. In Europe it is viewed as
addicting. The bottom line is; Once you take Cymbalta for 7 days the Cymbalta has
made its way through your body. If your body no longer has the Cymbalta in its
system, your body will react to the Cymbalta being gone.
Much like a person that eats a lot a sweets every day. Your body will react when
the sweet substance is not present. Call it addicting, as we would, call it a
dependence as United States physicians will, it is what it is. If you do not provide
the substance the body reacts and you also have mental feelings that are not
positive. We can get into the insulin discussion etc, but we are only talking about a
substance being present and then not and the body and mind reacting in a negative
manner.
What is the difference between Cymbalta and a Benzodiazepine?
Cymbalta is an SSRI medication, an antidepressant, used to treat depression and
anxiety. Benzodiazepines are prescribed mainly for the treatment of anxiety and
panic disorders but also prescribed off-label to treat depression.
These two types drug have different chemical components and were designed to
work on different brain receptors and neurotransmitters, but some of their effects
can be seen to overlap. Benzodiazepines are thought to mainly affect GABA
transmission, which can slow the central nervous system to reduce anxiety, while
Cymbalta is designed to block the reuptake of serotonin.
Benzodiazepines are known to be more prone to dependence/addiction than
Cymbalta. While the withdrawal symptoms are similar between both drugs,
Cymbalta’s half-life is 22-36 hours, and Benzodiazepines half-life is much lower.
Benzodiazepines can have more severe complications if abruptly stopped,
including seizures. For safe Benzodiazepine or Cymbalta withdrawal, either of
these drugs must be slowly tapered to allow the central nervous system and
neurochemistry to safely normalize.
Choosing to withdrawal from the Cymbalta first or the benzodiazepine first needs
to be evaluated. Use Chapter 23, The Science to decide is part of that equation.
Depending on the benzodiazepine you may be taking with the Cymbalta, if you
reduce the Cymbalta first it may make you go into withdrawal on the
benzodiazepine, even if you did not reduce the benzodiazepine.
How long does Cymbalta stay in your system after the last dosage?
Our founder, Jim Harper, made great strides with determining this question. Using
his DNA testing company in 2004-2005, Jim conducted hundreds of DNA tests to
determine how fast or slow medications took to metabolize. In roughly 34 percent
of the population the Cymbalta can take as long as 48 hours to clear the body. In
others, as little as 8 hours can occur for the Cymbalta to clear the body.
Depending on other habits you may have, Cymbalta could clear faster or even take
more time than the 48 hours. If you smoke cigarettes and stop smoking while
taking Cymbalta, the Cymbalta dosage you are taking will decrease by 15%. On
the other side of this, if you start smoking while taking Cymbalta, the Cymbalta
dosage will act as though it is 15% higher than you think it is. This is because
cigarettes induce an enzyme used to metabolize Cymbalta and anything using that
same pathway will shoot though much faster. Caffeine restricts that same enzyme,
so if you start or stop drinking coffee while taking Cymbalta you will either go into
withdrawal or feel an overdose, even though you have not changed the Cymbalta
dosage.
This is why The Road Back Program wants you to not change smoking habits or
caffeine habits during the Cymbalta taper.
Can you overdose on Cymbalta?
Yes, it is definitely possible for Cymbalta poisoning to occur. A substantial
Cymbalta overdose requires emergency medical intervention to prevent major
health problems. This list of Cymbalta overdose symptoms would be the same as
those Cymbalta side effects listed above, but more severe.
According to the National Institute of Health (NIH), the use of intravenous
benzodiazepines is sometimes required during Cymbalta overdose to prevent
seizures. Extra cooling measures must be used to reduce hyperthermia, always
under the direction of EMT or other medical staff attending to the patient.
Treatment for Cymbalta Withdrawal
Cymbalta has become one of the most frequently prescribed antidepressants in the
US. Of equal importance is that depressive disorders have become one of the most
frequently diagnosed conditions. These two facts together underscore two
important steps toward improved health:
Providing safe treatment programs for those who have decided on Cymbalta
withdrawal, and
Offering drug-free options to regain natural mental health without the need
for prescription medications.
The Road Back Program was described by Dr. Hyla Cass M.D. in this way:
Here's an essential handbook on how to safely and more easily wean yourself
(under medical supervision) off the heavily over-prescribed psychotropic
medications. I have used the program with my patients and it works!" Hyla
Cass M.D. Author of Supplement Your Prescription
Send an email to Jim Harper by using the Contact link on the top of this page or
read How to Get Off Psychoactive Drugs Safely by Jim Harper and follow the
program for Cymbalta withdrawal. Why Jim put his entire book on our website
for free is so you can instantly read the material and start this process if you are
ready now.
One last thing Jim asked us to provide at the bottom of each page of Cymbalta
descriptions:
There is Hope and There is a Solution
REFERENCES
Bailey, L.B., Gregory, J.F., (1999). “Polymorphisms of methylenetetrahydrofolate
reductase and other enzymes: metabolic significance, risks and impact on folate
requirement.” J Nutr 129(5): 919-22.
Bailey, L.B., Gregory, J.F., (1999). “Folate metabolism and requirements.” J Nutr
129(4): 779-82.
Basile, V.S., Masellis, M., Potkin, S.G., Kennedy, J.L., Pharmacogenomics in
schizophrenia: the quest for individualized therapy. Hum Mol Genet. 2002 Oct
1;11(20):2517-30
Blaisdell, J., Mohrenweiser, H., Jackson, Ferguson, J., Coulter, S., Chanas, S.,
Chanas, B., Xi, T., Ghanayem, B., Goldstein, J.A. Identification and functional
characterization of new potentially defective alleles of human CYP2C19.
Pharmacogenetics. 2002 Dec;12(9):703-11.
Bosron, W.F., Ting-Kai, L., (1986). “Genetic polymorphism of human liver
alcohol and aldehyde dehydrogenases, and their relationship to alcohol metabolism
and alcoholism.” Hepatology 6(3): 502 – 510.
Bradford, L.D., CYP2D6 allele frequency in European Caucasians, Asians,
Africans and their descendants. Pharmacogenomics. 2002 Mar;3 (2):229-43.
Brockmoller, J., et.al. Pharmacogenetic diagnosis of cytochrome P450
polymorphisms in clinical drug development and in drug treatment.
Pharmacogenetics. 2000:1:125-51.
Budziszewska B, Szymanska M, Leskiewicz M, Basta-Kaim A, Jaworska-Feil L,
Kubera M, Jantas D, Lason W. The decrease in JNK- and p38-MAP kinase activity
is accompanied by the enhancement of PP2A phosphate level in the brain of
prenatally stressed rats. J Physiol Pharmacol. 2010 Apr;61(2):207-15.
Carter CJ. Multiple genes and factors associated with bipolar disorder converge on
growth factor and stress activated kinase pathways controlling translation
initiation: implications for oligodendrocyte viability. Neurochem Int. 2007
Feb;50(3):461-90. Epub 2007 Jan 18. Review.
Ceriello, A., Giugliano, D., Quatraro, A., Lefebvre, P.J., Anti-oxidants show an
anti-hypertensive effect in diabetic and hypertensive subjects. Clin Sci
1991;81:739-42.
Chang, T.K., et al. Enhanced cyclophosphamide and ifosfamide activation in
primary human hepatocyte cultures: response to cytochrome P-450 inducers and
autoinduction by oxazaphosphorines. Cancer Res 1997; 57(10):1946-54.
Chango, A., Boisson, F., et al. (2000). “The effect of 677C-->T and 1298A-->C
mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase
activity in healthy subjects.” Br J Nutr 83(6): 593-6.
Charradi K, Sebai H, Elkahoui S, Ben Hassine F, Limam F, Aouani E. Grape Seed
Extract Alleviates High-Fat Diet-Induced Obesity and Heart Dysfunction by
Preventing Cardiac Siderosis. Cardiovasc Toxicol. 2011 Jan 14.
Cheng, T., Zhu, Z., et al. (2001). “Effects of multinutrient supplementation on
antioxidant defense systems in healthy human beings.” J Nutr Biochem 12(7): 388-
395.
Chida, M., Yokoi, T., Fukui, T., Kinoshita, M., Yokota, J., Kamataki, T., Detection
of three genetic polymorphisms in the 5’-flanking region and intron 1 of human
CYP1A2 in the Japanese population. Jpn J Cancer Res. 1999 Sep;90(9):899-902
Chistyakov, D. A., Savost’anov, et al. (2001). “Polymorphisms in the Mn-SOD
and EC-SOD genes and their relationship to diabetic neuropathy in type 1 diabetes
mellitus.” BMC Med Genet 2(1): 4.
Cosma, G., Crofts, F., et al. (1993). “Relationship between genotype and function
of the human CYP1A1 gene.” J Toxicol Environ Health 40(2-3): 309-16.
Cozza, K.L., Armstrong, S.C., Oesterheld, J.R., Drug Interaction principles for
Medical Practice. American Psychiatric Publishing Inc. (2003)
Chuang DM. Neuroprotective and neurotrophic actions of the mood stabilizer
lithium: can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol.
2004;16(1-2):83-90. Review.
Das J et al. Acetaminophen induced acute liver failure via oxidative stress and JNK
activation: protective role of taurine by the suppression of cytochrome P450 2E1.
Free Radic Res. 2010; 44(3): 340-55.
Gao N, Budhraja A, Cheng S, Yao H, Zhang Z, Shi X. Induction of apoptosis in
human leukemia cells by grape seed extract occurs via activation of c-Jun NH2-
terminal kinase.
Clin Cancer Res. 2009 Jan 1;15(1):140-9.
Ho, P.C., et al. Influence of CYP2C9 genotypes on the formation of a hepatotoxic
metabolite of valproic acid in human liver microsomes. Pharmacogenomics J 2003;
3(6):335-42.
Jeong SW, Kim LS, Hur D, Bae WY, Kim JR, Lee JH. Gentamicin-induced spiral
ganglion cell death: apoptosis mediated by ROS and the JNK signaling pathway.
Acta Otolaryngol. 2010 Jun;130(6):670-8.
Lam, Y.W.F., Gaedigk, A., Ereshefsy, L., et al: CYP2D6 inhibition by selective
serotonin reuptake inhibitors: analysis of achievable steady-state plasma
concentrations and the effect of ultrarapid metabolism at CYP2D6.
Pharmacotherapy 2002;22:1001-1006.
Lichtenstein AH, Appel LJ, Brands M et al. Diet and lifestyle recommendations
revision 2006: a scientific statement from the American Heart Association
Nutrition Committee. Circulation, 2006; 114: 82-96.
Lin CL, Lin JK. Epigallocatechin gallate (EGCG) attenuates high glucose-induced
insulin signaling blockade in human hepG2 hepatoma cells. Mol Nutr Food Res.
2008; 52(8): 930-9.
Liu H, Xiao Y, Xiong C, Wei A, Ruan J. Apoptosis induced by a new flavonoid in
human hepatoma HepG2 cells involves reactive oxygen species-mediated
mitochondrial dysfunction and MAPK activation. Eur J Pharmacol. 2011 Jan 15.
Madhyastha R, Madhyastha H, Nakajima Y, Omura S, Maruyama M. Curcumin
Facilitates Fibrinolysis and Cellular Migration during Wound Healing by
Modulating Urokinase Plasminogen Activator Expression. Pathophysiol Haemost
Thromb. 2010 Nov 12
Maheshwari A, Misro MM, Aggarwal A, Sharma RK, Nandan D. N-Acetyl-L-
cysteine counteracts oxidative stress and prevents H(2) O(2) induced germ cell
apoptosis through down-regulation of caspase-9 and JNK/c-Jun. Mol Reprod Dev.
2010 Dec 22. doi: 10.1002/mrd.21268.
Moon et al. Inhibitory effect of (-)-epigallocatechin-3-gallate on lipid accumulation
of 3T3-L1 cells. Obesity (Silver Spring). 2007; 15(11): 2571-82.
Pan J, Xiao Q, Sheng CY, Hong Z, Yang HQ, Wang G, Ding JQ, Chen SD.
Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3)
attenuates dopaminergic neuronal damage in mouse model of Parkinson’s disease.
Neurochem Int. 2009 Jun;54(7):418-25. Epub 2009 Jan 29.
Ramerstorfer J, Furtmüller R, Sarto-Jackson I, Varagic Z, Sieghart W, Ernst M.
The GABAA Receptor malpha?+ebetaS- Interface: A Novel Target for Subtype
Selective Drugs. J Neurosci. 2011 Jan 19;31(3):870-7
Romier-Crouzet B, Van De Walle J, During A, Joly A, Rousseau C, Henry O,
Larondelle Y, Schneider YJ. Inhibition of inflammatory mediators by polyphenolic
plant extracts in human intestinal Caco-2 cells. Food Chem Toxicol. 2009
Jun;47(6):1221-30. Epub 2009 Feb 20.
Spiliotaki M, Salpeas V, Malitas P, Alevizos V, Moutsatsou P. Altered
glucocorticoid receptor signaling cascade in lymphocytes of bipolar disorder
patients. Psychoneuroendocrinology. 2006 Jul;31(6):748-60. Epub 2006 Apr 18.
Stornetta RL, Zhu JJ. Ras and Rap Signaling in Synaptic Plasticity and Mental
Disorders. Neuroscientist. 2010 Apr 29.
Tian H, Zhang G, Li H, Zhang Q. Antio
xidant NAC and AMPA/KA receptor
antagonist DNQX inhibited JNK3 activation following global ischemia in rat
hippocampus. Neurosci Res. 2003 Jun;46(2):191-7.
Waltner-Low ME et al. Epigallocatechin gallate, a constituent of green tea,
represses hepatic glucose production. J Biol Chem. 2002; 277(38): 34933-40.
Wu H et al. JNK-dependent NFATc1 pathway positively regulates IL-13 gene
expression induced by (-)-epigallocatechin-3-gallate in human basophilic KU812
cells. Free Radic Biol Med. 2009; 47(7): 1028-38.
Wu N et al. Taurine prevents free fatty acid-induced hepatic insulin resistance in
association with inhiditing JNK1 activation and improving insulin signaling in
vitro. Diabetes Res Clin Pract. 2010; 90(3): 288-90.
Xie N, Wang C, Lin Y, Li H, Chen L, Zhang T, Sun Y, Zhang Y, Yin D, Chi Z.
The role of p38 MAPK in valproic acid induced microglia apoptosis. Neurosci
Lett. 2010 Sep 20;482(1):51-6. Epub 2010 Jul 16.
Xu Y, Hou XY, Liu Y, Zong YY. Different protection of K252a and N-acetyl-L-
cysteine against amyloid-beta peptide-induced cortical neuron apoptosis involving
inhibition of MLK3-MKK7-JNK3 signal cascades. J Neurosci Res. 2009
Mar;87(4):918-27.
Yaniv SP, Lucki A, Klein E, Ben-Shachar D. Dexamethasone enhances the
norepinephrine-induced ERK/MAPK intracellular pathway possibly via
dysregulation of the alpha2-adrenergic receptor: implications for antidepressant
drug mechanism of action. Eur J Cell Biol. 2010 Sep;89(9):712-22.
Zhang F, Lau SS, Monks TJ. The Cytoprotective Effect of N-acetyl-L-cysteine
against ROS-induced Cytotoxicity is Independent of its Ability to Enhance
Glutathione Synthesis. Toxicol Sci. 2010 Dec 6.
Cymbalta Withdrawal Solution,
Sertraline Side Effects, Treatment
Options
Cymbalta Withdrawal Symptoms
The majority of people attempting
Cymbalta withdrawal experience an
antidepressant withdrawal syndrome.
This is also known as Cymbalta
discontinuation syndrome in the
United States. In Europe it is call
Cymbalta withdrawal side effects.
The F.D.A. estimates 10% of those
experiencing Cymbalta withdrawal
will go back up on the Cymbalta
because the withdrawal symptoms are
too severe.
If you want to read the short version
of how to handle Cymbalta withdrawal
side effects Click here.
Page opens new browser window.
The most common and debilitating
Cymbalta withdrawal side effect is
called "brain zaps." Brain zaps are
described by people experiencing it as
a; electrical jolt that tends to run from
base of the neck up into their head.
Another side effect that tends to run
with brain zaps is a shiver, a feeling
as your head is floating, dizziness,
and/or a whirling sensation in the
head.
These symptoms can come in waves
or even be persistent.
The good news; in 2002, our founder,
Jim Harper, discovered the correct
type of Omega 3 taken in the right
quantity will eliminate these
devastating head symptoms quickly.
Usually within a couple of hours.
The body in a normal state uses the
oil from our diet, specifically from
omega 3 found in fish, to build and
replenish the end point of areas in the
brain that sends and receives electrical
signals. We are using easy to
understand terminology here so it is
easy to understand. Let's leave the
technical jargon to physicians.
These brain zaps have nothing to do
with serotonin levels or other made up
reasons. It is simple really; our body
works in a very natural way with how
it uses amino acids, proteins, fats in
food and all other diet items to
maintain a balance. When you
introduce any toxin that disrupts these
processes the body reacts.
The most common Cymbalta
withdrawal symptoms reported
include:
Flu like symptoms
Insomnia
Anxiety
Brain zaps
Tremors
Diarrhea
Vomiting
Increased suicidal ideation
Nausea
Headache
Mania
Hypomania
Ringing in the ears
Aggression
Confusion
Imbalance
Mood swings
Please note: These are the most
common Cymbalta withdrawal side
effects but far from all potential
Cymbalta withdrawal side effects.
There is a warning the FDA has put a
black box warning on Cymbalta.
WARNING: SUICIDAL
THOUGHTS AND
BEHAVIORSSee full prescribing
information for complete boxed
warning. Antidepressants increased
the risk of suicidal thoughts and
behaviorsin pediatric and young
adult patients (5.1) Closely monitor
for clinical worsening and
emergence of suicidalthoughts and
behaviors
You may have been prescribed
Cymbalta within a very short doctor
visit. There was no investigation into
other life factors, lab testing, or any
conversation about what side effects
might present. The failings of this
approach may cause quite a burden on
the patient.
Depression, insomnia, anxiety,
fibromyalgia, and other symptoms
that Cymbalta is often prescribed for
might stem from; diminished vitamin
D levels, over active JNK gene,
specific proteins that need to be
silenced, dietary concerns and food
allergies, mitochondrial dysfunction,
neurotoxic accumulation, and many
other reasons. A full physical from an
understanding physician is ideal,
before prescribing Cymbalta.
Do Your Symptoms Require
Cymbalta?
The Road Back Program uses
nutritional supplements to help with
the Cymbalta withdrawal. Most
people feel a very fast relief from the
Cymbalta withdrawal once they begin
taking the supplements and we feel
the odds are high; if would have taken
nutritional supplements like these
before starting the Cymbalta you
would have been prescribed the
Cymbalta in the first place.
In 2007, Jim Harper was giving a
speech to a group of psychiatrists in
Ireland and during his talk he
mentioned his mother just passed
away 30 days ago. He went on to
describe how he made sure to take his
JNK Formula each day to help the
body cope with the stress being put on
it do to his loss. He went on to say,
"The JNK Formula will not remove
the emotional loss and how I feel but
it will keep the body strong during my
time to grieve."
How Do You Survive Cymbalta
Withdrawal?
Surviving Cymbalta withdrawal
depends on what you do at this very
moment. If you keep doing the same
thing you have been doing and you
are in a heavy Cymbalta withdrawal,
nothing will change for the positive,
That is a given.
If you decide to do the Cymbalta
withdrawal as an inpatient in a drug
rehab center DO NOT DO THE 9
DAY PLAN BECAUSE THAT
WHAT INSURANCE ALLOWS.
Over the past 22 years I have worked
with far to many people who were
sold on a rehab facility, stayed the 9
days because insurance would only
pay for that amount of time. The
unscrupulous facility took them off
the Cymbalta in 9 days as they
promised and by the time the person
got off the airplane after their return
home they were in full withdrawal.
You can't do a Cymbalta withdrawal
in 9 days.
The Road Back Program can
normally help you get back on your
feet again but the rehab facility
approach of this type is not worth
the price you will pay mentally and
physically.
You will find a few other outpatient
Cymbalta withdrawal programs on the
internet now and Jim Harper is not
aware of one that will cause you harm
like the rehab facility's mentioned.
However, every other program on the
internet was trained by Jim Harper
years ago and they are doing what Jim
Harper and The Road Back did during
that time frame. Almost 2 decades ago
Jim Harper trained several physicians
and good intentioned people how to
get a patient off Cymbalta. Jim went
in to detail of the process and what
nutritional supplements were used and
why they were used. At that time of
The Road Back the success rate was
not as high as desired and over the
following years Jim changed the
formulas used with the supplements
several times to use new information
with DNA testing. Long story short;
you will likely wind up using a
Cymbalta withdrawal approach The
Road Back used in 2003, that was
scrapped for something more
successful.
If you are currently in Cymbalta
withdrawal, send Jim Harper an email
and he will personally guide you
through the process so you can get
back on your feet quickly and have a
very successful Cymbalta withdrawal.
It does not matter if you have been on
Cymbalta for 1 month or 20 years.
Recovery can happen and the good
part is; it does not take more time
because you have been taking
Cymbalta for years.
When Do Cymbalta Withdrawal
Symptoms Start When
Discontinuing / Quitting Cymbalta?
Cymbalta withdrawal usually begins
between day 1 and day 3 of adjusting
the Cymbalta. For some people this is
not the case but eventually most
everyone hits some dosage of the
Cymbalta when reducing that jars
them. Cymbalta withdrawal begins
and they have no idea what they
should do. Their physician does not
know what to do. They wind up in a
spiral downward and wind up on a
new medication to try and stop the
Cymbalta withdrawal. The best case
is the additional drug does that but
you are now on 2 drugs instead of
only Cymbalta.
What is Cymbalta?
Cymbalta (sertraline) is an
antidepressant medication developed
in the 1970s
with FDA approval
granted in 1991. This SSRI drug is
prescribed in treating adult depressive
disorders (MDD), panic disorder,
obsessive compulsory disorders
(OCD), social anxiety (SAD), post-
traumatic stress disorders (PTSD),
and premenstrual dysphoric disorder
(PMDD).
If you have anxiety before taking
Cymbalta, or anxiety begins while
taking Cymbalta, odds are the anxiety
will continue to get worse. Cymbalta
alters dopamine much like the
antidepressant Effexor and anxiety is
a byproduct of these two drugs.
What Is Cymbalta Used For?
Cymbalta (sertraline) is an
antidepressant medication approved to
treat adult MDD (major depressive
disorder). The Black Box warning on
the drug’s packaging mentions that
the drug should not be prescribed to
anyone under the age of 25, due to
heightened risk of suicide. There is an
exception to this for patients under the
age of 25 who have been diagnosed
with OCD (obsessive-compulsive
disorder).
Potential suicidality is associated with
all Cymbalta and may be a concern
leading to consider Cymbalta
withdrawal, which is recommended to
be done always under medical or
caregiver monitoring.
Adult-only approved uses for the
drug provided in a clinical or
treatment setting include:
MDD: Major Depressive
Disorder<
PTSD: Post-traumatic stress
disorder
PD: Panic disorder
SAD: Social anxiety disorder
OCD: Obsessive-compulsive
disorder
PMDD: Premenstrual
dysphoric disorder
Cymbalta Side Effects
The full list of Cymbalta side effects
is quite staggering. In 2004, Jim
Harper used the Freedom of
Information Act to get the full list of
Cymbalta side effects. Jim received
the information and it is 500 sheets of
letter size paper, single space, a
number 10 font size, 3 columns per
page. In other words, thousands of
known potential Cymbalta side effects
were disclosed.
Some of the other Cymbalta and
Cymbalta withdrawal side effects:
Serotonin syndrome: A life-
threatening condition
requiring immediate medical
care in a hospital emergency
clinic or ICU. Symptoms to
watch for include sudden
fever, losing consciousness,
inability to move or speak,
copious sweating, dilated
pupils, chills, tremors,
convulsions, diarrhea,
agitation, restlessness, racing
heart, etc.
Suicidal thoughts (common)
Suicide attempt (common)
Hyperkinesis (muscle spasms,
movement disorder)
Worsened depression
Aggression
Paranoia (rare)
Anxiety
Mania (common)
Convulsions
Unconsciousness
Coma
Teeth grinding
Akathisia (relentless internal
restlessness and discomfort
marked by repeated motions,
pacing, rocking, etc., that can
lead to suicidal thoughts as a
means of relief)
Tachycardia (racing heart,
even when the body is at rest)
Rash
Itching
Burning, crawling feeling in
the skin
Fever
Tics, sudden jerky
movements, myoclonus
Emotional blunting
Behavioral apathy, SSRI-
induced-indifference
Pain on urination or difficulty
urinating
Cloudy urine
Headache
Sexual impairments, i.e.,
anorgasmia, inability to
ejaculate, lowered libido
Mood swings
Pain around the eyes or eye
sockets
Sleepiness
Bladder pain
Prickling skin sensation
Numbness
Sensory disturbances
Insomnia
Depersonalization (common)
Nervousness
Nightmares (paroniria)
Hostility
Nausea
Diarrhea
Weight gain
Some documented Cymbalta birth
defects and injuries include:
PPHN or persistent pulmonary
hypertension of the newborn, a
heart and lung condition which
can result in respiratory failure,
decreased oxygen to the brain,
and multiple organ injuries.
Congenital Heart Defects
connected to Cymbalta and
other SSRIs include ventricular
septal defects and atrial septal
defects, also referred to as
“holes in the heart”, related to
heart murmurs, suppressed
appetite, breathing difficulties,
tiredness, inadequate growth,
etc.
Increased Risk of Autism has
been extensively reported but
evidence has not yet been
considered conclusive enough
for regulatory bodies to ban
prescribing to pregnant women.
Increased Risk of Clubfoot
connected to SSRIs during
pregnancy as reported by
NIMH, where sertraline
exposure had the highest
increase in clubfoot of all
SSRIs.
Increased risk of
atrial/ventricular defects and
craniosynostosis was reported
in a Canadian study from 1998
to 2010 and published in the
June 2015 issue of the
American Journal of
Gynecology & Obstetrics.
Cymbalta Withdrawal, What to Expect
If using The Road Back Program you
should expect to feel a lot better
within the first couple days of the
program. If you do nothing, expect to
continue to feel as you do now.
Possibly worse as time goes on. The
chance of feeling better if you do
nothing is nil.
In 1999, The Road Back only had
people taper the Cymbalta gradually
and slowly. They still suffered.
Around 50% could get off the
Cymbalta but most went back on the
Cymbalta because they continual
Cymbalta withdrawal side effects
would not diminish or go away.
We wish there was a better answer for
you than the above but with working
with over 19 million people over the
last 22 years, the truth is the truth. No
way to water it down to make it sound
better.
Some may think it is just their
depression returning but who would
not feel depressed if they were still
going through Cymbalta withdrawal
months after stopping the Cymbalta.
We can't stress enough; what you do
or do not do at this moment in time is
critical for your future. Take your
time if at all possible. If you have
brain zaps go buy any omega 3 fish
oil, even the wrong omega 3 fish oil
will help somewhat.
While you read this you may want to
pause and go take a walk. Look at the
trees, the sky or anything off in the
distance. Getting your attention off
your mind and body may do wonders.
Keep this close to your heart; There is
Hope and There is a Solution. We are
speaking directly to YOU.
A 30 day supply of the nutritional
supplements will cost you around
$80. If you feel it is worth $80 to take
a chance that all of this can go away
in a couple of days, then take that
chance. Over the past 22 years many
have sent an email to Jim Harper and
said they were not sure what to do
about the Cymbalta withdrawal. Even
after reading this information. The
people that tried something else
generally came back within a few
months and were in worse shape than
before. We do not want this to happen
to you. But if is; Jim will still be here
to assist.
Can Cymbalta Make Depression Worse?
Common sense answers this question.
If depression is one side effect of
taking Cymbalta then Cymbalta can
cause depression. You do stand a
greater chance of Cymbalta causing
depression during withdrawal than
while simply taking the Cymbalta as
prescribed. The depression during
Cymbalta withdrawal can be due to
the other Cymbalta withdrawal side
effects you are experiencing. Who
would not start to get depressed if you
have anxiety from morning to night,
can't sleep and your head feels like it
is on fire.
Cymbalta Aggression in Children
Children are more prone to aggression
when taking Cymbalta than adults. It
occurs in 10-20% of children taking
any SSRI antidepressant. Two clinical
trials performed by Pfizer, aggression
was the most common reason noted
for Cymbalta discontinuation.
Can You Get Addicted to Cymbalta?
Yes and no. This is where Cymbalta
dependence is a matter of wording.
Medically speaking in the United
States Cymbalta is not addicting. In
Europe it is viewed as addicting. The
bottom line is; Once you take
Cymbalta for 7 days the Cymbalta has
made its way through your body. If
your body no longer has the Cymbalta
in its system, your body will react to
the Cymbalta being gone.
Much like a person that eats a lot a
sweets every day. Your body will
react when the sweet substance is not
present. Call it addicting, as we
would, call it a dependence as United
States physicians will, it is what it is.
If you do not provide the substance
the body reacts and you also have
mental feelings that are not positive.
We can get into the insulin discussion
etc, but we are only talking about a
substance being present and then not
and the body and mind reacting in a
negative manner.
What is the difference between
Cymbalta and a Benzodiazepine?
Cymbalta is an SSRI medication, an
antidepressant, used to treat
depression and anxiety.
Benzodiazepines are prescribed
mainly for the treatment of anxiety
and panic disorders but also
prescribed off-label to treat
depression.
These two types drug have different
chemical components and were
designed to work on different brain
receptors and neurotransmitters, but
some of their effects can be seen to
overlap. Benzodiazepines are thought
to mainly affect GABA transmission,
which can slow the central nervous
system to reduce anxiety, while
Cymbalta is designed to block the
reuptake of serotonin.
Benzodiazepines are known to be
more prone to dependence/addiction
than Cymbalta. While the withdrawal
symptoms are similar between both
drugs, Cymbalta’s half-life is 22-36
hours, and Benzodiazepines half-life
is much lower. Benzodiazepines can
have more severe complications if
abruptly stopped, including seizures.
For safe Benzodiazepine or Cymbalta
withdrawal, either of these drugs must
be slowly tapered to allow the central
nervous system and neurochemistry to
safely normalize.
Choosing to withdrawal from the
Cymbalta first or the benzodiazepine
first needs to be evaluated. Use
Chapter 23, The Science to decide is
part of that equation. Depending on
the benzodiazepine you may be taking
with the Cymbalta, if you reduce the
Cymbalta first it may make you go
into withdrawal on the
benzodiazepine, even if you did not
reduce the benzodiazepine.
How long does Cymbalta stay in
your system after the last dosage?
Our founder, Jim Harper, made great
strides with determining this question.
Using his DNA testing company in
2004-2005, Jim conducted hundreds
of DNA tests to determine how fast or
slow medications took to metabolize.
In roughly 34 percent of the
population the Cymbalta can take as
long as 48 hours to clear the body. In
others, as little as 8 hours can occur
for the Cymbalta to clear the body.
Depending on other habits you may
have, Cymbalta could clear faster or
even take more time than the 48
hours. If you smoke cigarettes and
stop smoking while taking Cymbalta,
the Cymbalta dosage you are taking
will decrease by 15%. On the other
side of this, if you start smoking
while taking Cymbalta, the Cymbalta
dosage will act as though it is 15%
higher than you think it is. This is
because cigarettes induce an enzyme
used to metabolize Cymbalta and
anything using that same pathway will
shoot though much faster. Caffeine
restricts that same enzyme, so if you
start or stop drinking coffee while
taking Cymbalta you will either go
into withdrawal or feel an overdose,
even though you have not changed the
Cymbalta dosage.
This is why The Road Back Program
wants you to not change smoking
habits or caffeine habits during the
Cymbalta taper.
Can you overdose on Cymbalta?
Yes, it is definitely possible for
Cymbalta poisoning to occur. A
substantial Cymbalta overdose
requires emergency medical
intervention to prevent major health
problems. This list of Cymbalta
overdose symptoms would be the
same as those Cymbalta side effects
listed above, but more severe.
According to the National Institute of
Health (NIH), the use of intravenous
benzodiazepines is sometimes
required during Cymbalta overdose to
prevent seizures. Extra cooling
measures must be used to reduce
hyperthermia, always under the
direction of EMT or other medical
staff attending to the patient.
Treatment for Cymbalta Withdrawal
Cymbalta has become one of the most
frequently prescribed antidepressants
in the US. Of equal importance is that
depressive disorders have become one
of the most frequently diagnosed
conditions. These two facts together
underscore two important steps
toward improved health:
Providing safe treatment
programs for those who have
decided on Cymbalta
withdrawal, and
Offering drug-free options to
regain natural mental health
without the need for
prescription medications.
The Road Back Program was
described by Dr. Hyla Cass M.D.
in this way:
Here's an essential handbook on
how to safely and more easily
wean yourself (under medical
supervision) off the heavily over-
prescribed psychotropic
medications. I have used the
program with my patients and it
works!" Hyla Cass M.D. Author
of Supplement Your Prescription
Send an email to Jim Harper by
using the Contact link on the top of
this page or read How to Get Off
Psychoactive Drugs Safely by Jim
Harper and follow the program for
Cymbalta withdrawal.
Why Jim put his entire book on our website
for free is so you can instantly read
the material and start this process
if you are ready now.
One last thing Jim asked us to
provide at the bottom of each page
of Cymbalta descriptions:
There is Hope and There is a
Solution
REFERENCES
Bailey, L.B., Gregory, J.F., (1999).
“Polymorphisms of
methylenetetrahydrofolate
reductase and other enzymes: metabolic
significance, risks and impact on folate
requirement.” J Nutr 129(5): 919-22.
Bailey, L.B., Gregory, J.F., (1999).
“Folate metabolism and requirements.” J
Nutr
129(4): 779-82.
Basile, V.S., Masellis, M., Potkin, S.G.,
Kennedy, J.L., Pharmacogenomics in
schizophrenia: the quest for
individualized therapy. Hum Mol Genet.
2002 Oct
1;11(20):2517-30
Blaisdell, J., Mohrenweiser, H., Jackson,
Ferguson, J., Coulter, S., Chanas, S.,
Chanas, B., Xi, T., Ghanayem, B.,
Goldstein, J.A. Identification and
functional
characterization of new potentially
defective alleles of human CYP2C19.
Pharmacogenetics. 2002 Dec;12(9):703-
11.
Bosron, W.F., Ting-Kai, L., (1986).
“Genetic polymorphism of human liver
alcohol and aldehyde dehydrogenases,
and their relationship to alcohol
metabolism
and alcoholism.” Hepatology 6(3): 502 –
510.
Bradford, L.D., CYP2D6 allele
frequency in European Caucasians,
Asians,
Africans and their descendants.
Pharmacogenomics. 2002 Mar;3 (2):229-
43.
Brockmoller, J., et.al. Pharmacogenetic
diagnosis of cytochrome P450
polymorphisms in clinical drug
development and in drug treatment.
Pharmacogenetics. 2000:1:125-51.
Budziszewska B, Szymanska M,
Leskiewicz M, Basta-Kaim A, Jaworska-
Feil L,
Kubera M, Jantas D, Lason W. The
decrease in JNK- and p38-MAP kinase
activity
is accompanied by the enhancement of
PP2A phosphate level in the brain of
prenatally stressed rats. J Physiol
Pharmacol. 2010 Apr;61(2):207-15.
Carter CJ. Multiple genes and factors
associated with bipolar disorder
converge on
growth factor and stress activated kinase
pathways controlling translation
initiation: implications for
oligodendrocyte viability. Neurochem
Int. 2007
Feb;50(3):461-90. Epub 2007 Jan 18.
Review.
Ceriello, A., Giugliano, D., Quatraro, A.,
Lefebvre, P.J., Anti-oxidants show an
anti-hypertensive effect in diabetic and
hypertensive subjects. Clin Sci
1991;81:739-42.
Chang, T.K., et al. Enhanced
cyclophosphamide and ifosfamide
activation in
primary human hepatocyte cultures:
response to cytochrome P-450 inducers
and
autoinduction by oxazaphosphorines.
Cancer Res 1997; 57(10):1946-54.
Chango, A., Boisson, F., et al. (2000).
“The effect of 677C-->T and 1298A-->C
mutations on plasma homocysteine and
5,10-methylenetetrahydrofolate
reductase
activity in healthy subjects.” Br J Nutr
83(6): 593-6.
Charradi K, Sebai H, Elkahoui S, Ben
Hassine F, Limam F, Aouani E. Grape
Seed
Extract Alleviates High-Fat Diet-Induced
Obesity and Heart Dysfunction by
Preventing Cardiac Siderosis. Cardiovasc
Toxicol. 2011 Jan 14.
Cheng, T., Zhu, Z., et al. (2001). “Effects
of multinutrient supplementation on
antioxidant defense systems in healthy
human beings.” J Nutr Biochem 12(7):
388-
395.
Chida, M., Yokoi, T., Fukui, T.,
Kinoshita, M., Yokota, J., Kamataki, T.,
Detection
of three genetic polymorphisms in the 5’-
flanking region and intron 1 of human
CYP1A2 in the Japanese population. Jpn
J Cancer Res. 1999 Sep;90(9):899-902
Chistyakov, D. A., Savost’anov, et al.
(2001). “Polymorphisms in the Mn-SOD
and EC-SOD genes and their relationship
to diabetic neuropathy in type 1 diabetes
mellitus.” BMC Med Genet 2(1): 4.
Cosma, G., Crofts, F., et al. (1993).
“Relationship between genotype and
function
of the human CYP1A1 gene.” J Toxicol
Environ Health 40(2-3): 309-16.
Cozza, K.L., Armstrong, S.C.,
Oesterheld, J.R., Drug Interaction
principles for
Medical Practice. American Psychiatric
Publishing Inc. (2003)
Chuang DM. Neuroprotective and
neurotrophic actions of the mood
stabilizer
lithium: can it be used to treat
neurodegenerative diseases? Crit Rev
Neurobiol.
2004;16(1-2):83-90. Review.
Das J et al. Acetaminophen induced
acute liver failure via oxidative stress
and JNK
activation: protective role of taurine by
the suppression of cytochrome P450
2E1.
Free Radic Res. 2010; 44(3): 340-55.
Gao N, Budhraja A, Cheng S, Yao H,
Zhang Z, Shi X. Induction of apoptosis
in
human leukemia cells by grape seed
extract occurs via activation of c-Jun
NH2-
terminal kinase.
Clin Cancer Res. 2009 Jan 1;15(1):140-
9.
Ho, P.C., et al. Influence of CYP2C9
genotypes on the formation of a
hepatotoxic
metabolite of valproic acid in human
liver microsomes. Pharmacogenomics J
2003;
3(6):335-42.
Jeong SW, Kim LS, Hur D, Bae WY,
Kim JR, Lee JH. Gentamicin-induced
spiral
ganglion cell death: apoptosis mediated
by ROS and the JNK signaling pathway.
Acta Otolaryngol. 2010 Jun;130(6):670-
8.
Lam, Y.W.F., Gaedigk, A., Ereshefsy,
L., et al: CYP2D6 inhibition by selective
serotonin reuptake inhibitors: analysis of
achievable steady-state plasma
concentrations and the effect of
ultrarapid metabolism at CYP2D6.
Pharmacotherapy 2002;22:1001-1006.
Lichtenstein AH, Appel LJ, Brands M et
al. Diet and lifestyle recommendations
revision 2006: a scientific statement
from the American Heart Association
Nutrition Committee. Circulation, 2006;
114: 82-96.
Lin CL, Lin JK. Epigallocatechin gallate
(EGCG) attenuates high glucose-induced
insulin signaling blockade in human
hepG2 hepatoma cells. Mol Nutr Food
Res.
2008; 52(8): 930-9.
Liu H, Xiao Y, Xiong C, Wei A, Ruan J.
Apoptosis induced by a new flavonoid in
human hepatoma HepG2 cells involves
reactive oxygen species-mediated
mitochondrial dysfunction and MAPK
activation. Eur J Pharmacol. 2011 Jan
15.
Madhyastha R, Madhyastha H, Nakajima
Y, Omura S, Maruyama M. Curcumin
Facilitates Fibrinolysis and Cellular
Migration during Wound Healing by
Modulating Urokinase Plasminogen
Activator Expression. Pathophysiol
Haemost
Thromb. 2010 Nov 12
Maheshwari A, Misro MM, Aggarwal A,
Sharma RK, Nandan D. N-Acetyl-L-
cysteine counteracts oxidative stress and
prevents H(2) O(2) induced germ cell
apoptosis through down-regulation of
caspase-9 and JNK/c-Jun. Mol Reprod
Dev.
2010 Dec 22. doi: 10.1002/mrd.21268.
Moon et al. Inhibitory effect of (-)-
epigallocatechin-3-gallate on lipid
accumulation
of 3T3-L1 cells. Obesity (Silver Spring).
2007; 15(11): 2571-82.
Pan J, Xiao Q, Sheng CY, Hong Z, Yang
HQ, Wang G, Ding JQ, Chen SD.
Blockade of the translocation and
activation of c-Jun N-terminal kinase 3
(JNK3)
attenuates dopaminergic neuronal
damage in mouse model of Parkinson’s
disease.
Neurochem Int. 2009 Jun;54(7):418-25.
Epub 2009 Jan 29.
Ramerstorfer J, Furtmüller R, Sarto-
Jackson I, Varagic Z, Sieghart W, Ernst
M.
The GABAA Receptor malpha?+ebetaS-
Interface: A Novel Target for Subtype
Selective Drugs. J Neurosci. 2011 Jan
19;31(3):870-7
Romier-Crouzet B, Van De Walle J,
During A, Joly A, Rousseau C, Henry O,
Larondelle Y, Schneider YJ. Inhibition
of inflammatory mediators by
polyphenolic
plant extracts in human intestinal Caco-2
cells. Food Chem Toxicol. 2009
Jun;47(6):1221-30. Epub 2009 Feb 20.
Spiliotaki M, Salpeas V, Malitas P,
Alevizos V, Moutsatsou P. Altered
glucocorticoid receptor signaling cascade
in lymphocytes of bipolar disorder
patients. Psychoneuroendocrinology.
2006 Jul;31(6):748-60. Epub 2006 Apr
18.
Stornetta RL, Zhu JJ. Ras and Rap
Signaling in Synaptic Plasticity and
Mental
Disorders. Neuroscientist. 2010 Apr 29.
Tian H, Zhang G, Li H, Zhang Q. Antio
xidant NAC and AMPA/KA receptor
antagonist DNQX inhibited JNK3
activation following global ischemia in
rat
hippocampus. Neurosci Res. 2003
Jun;46(2):191-7.
Waltner-Low ME et al. Epigallocatechin
gallate, a constituent of green tea,
represses hepatic glucose production. J
Biol Chem. 2002; 277(38): 34933-40.
Wu H et al. JNK-dependent NFATc1
pathway positively regulates IL-13 gene
expression induced by (-)-
epigallocatechin-3-gallate in human
basophilic KU812
cells. Free Radic Biol Med. 2009; 47(7):
1028-38.
Wu N et al. Taurine prevents free fatty
acid-induced hepatic insulin resistance in
association with inhiditing JNK1
activation and improving insulin
signaling in
vitro. Diabetes Res Clin Pract. 2010;
90(3): 288-90.
Xie N, Wang C, Lin Y, Li H, Chen L,
Zhang T, Sun Y, Zhang Y, Yin D, Chi Z.
The role of p38 MAPK in valproic acid
induced microglia apoptosis. Neurosci
Lett. 2010 Sep 20;482(1):51-6. Epub
2010 Jul 16.
Xu Y, Hou XY, Liu Y, Zong YY.
Different protection of K252a and N-
acetyl-L-
cysteine against amyloid-beta peptide-
induced cortical neuron apoptosis
involving
inhibition of MLK3-MKK7-JNK3 signal
cascades. J Neurosci Res. 2009
Mar;87(4):918-27.
Yaniv SP, Lucki A, Klein E, Ben-
Shachar D. Dexamethasone enhances the
norepinephrine-induced ERK/MAPK
intracellular pathway possibly via
dysregulation of the alpha2-adrenergic
receptor: implications for antidepressant
drug mechanism of action. Eur J Cell
Biol. 2010 Sep;89(9):712-22.
Zhang F, Lau SS, Monks TJ. The
Cytoprotective Effect of N-acetyl-L-
cysteine
against ROS-induced Cytotoxicity is
Independent of its Ability to Enhance
Glutathione Synthesis. Toxicol Sci. 2010
Dec 6.